Physician profile
Krishna Patel
NPI 1992159537
$6,980.39
in general payments reported to CMS, 2019-2025
21 companies · $3,599 in 2025
The $3,599 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $418 · 2024: $2,963 · 2025: $3,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,148 · Consulting Fee: $2,800 · Travel and Lodging: $32.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,147.56 |
| Consulting Fee | $2,800.00 |
| Travel and Lodging | $32.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,467.64 | 2024-2025 | Tremfya, Stelara |
| Abbvie INC. | $2,442.82 | 2023-2025 | |
| Celgene Corporation | $400.74 | 2023-2024 | Zeposia |
| Lilly USA, LLC | $309.20 | 2024-2025 | Omvoh |
| Pfizer INC. | $279.13 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $268.26 | 2023-2025 | Entyvio, Eohilia |
| Janssen Scientific Affairs, LLC | $193.67 | 2025 | Tremfya |
| Steris Corporation | $143.26 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.92 | 2024 | Xifaxan, Plenvu, Trulance |
| Madrigal Pharmaceuticals | $68.08 | 2025 | Rezdiffra |
| Genzyme Corporation | $50.08 | 2024 | |
| Evoke Pharma, INC. | $33.08 | 2024 | |
| Celltrion USA INC. | $31.60 | 2025 | Vegzelma |
| E.R. Squibb & Sons, L.L.C. | $29.87 | 2024 | |
| Phathom Pharmaceuticals, INC. | $29.30 | 2024-2025 | Voquezna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $26.52 | 2025 | Iqirvo |
| Qol Medical, LLC | $25.48 | 2025 | Sucraid |
| Biocon Biologics INC | $24.95 | 2025 | Yesintek |
| Braintree Laboratories, INC. | $23.03 | 2024 | Sutab, Suflave |
| Sun Pharmaceutical Industries INC. | $20.18 | 2025 | |
| Echosens North America, INC. | $13.58 | 2024 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishna Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.